ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,222.68
      0.16%
      US Tech 100
      17,650.00
      0.05%
      Dow Jones
      39,512.84
      0.32%
      Brent Oil
      82.585
      0.00%
      Bitcoin
      60,952.64
      0.25%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. uniQure NV (QURE)

      7. uniQure NV (QURE) News

      QURE

      uniQure NV (QURE)

      uniQure NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:QURE
      DateTimeSourceHeadlineSymbolCompany
      05/07/20248:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      05/07/20247:57AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
      05/07/20247:05AMGlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
      03/05/20245:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      03/05/20245:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      03/05/20244:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      03/05/20244:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      02/28/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
      02/28/20248:29AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
      02/28/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      02/28/20247:05AMGlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
      02/26/20244:46PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
      02/26/20244:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
      02/13/20244:33PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
      12/19/20237:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      12/19/20237:05AMGlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
      12/11/20237:30PMPR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
      12/08/20237:05AMGlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
      11/29/20237:05AMGlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
      11/17/20236:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      11/07/20237:52AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
      11/07/20237:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
      11/07/20237:05AMGlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
      10/27/202310:00AMPR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
      10/26/20232:38PMPR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
      10/26/20232:14PMPR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
      10/24/20237:05AMGlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
      10/06/20236:33AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
      10/06/20236:32AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QUREuniQure NV
      10/05/20234:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
       Showing the most relevant articles for your search:NASDAQ:QURE